The FDA has approved clesrovimab, marketed as Enflonsia, for the prevention of RSV lower respiratory tract disease in ...

The chair of the CDC’s newly remade vaccine advisory committee said Wednesday that the committee will be reviewing existing ...

The Centers for Disease Control and Prevention's vaccine advisory committee is set to meet for the first time since Health ...

Nearly three-quarters of infants were immunized against respiratory syncytial virus through maternal vaccination or ...

The Hong Kong-based financial advisory firm Charleswood Limited, which focuses on the biopharmaceutical industry, has publish ...

At the first meeting of a controversial new group of vaccine advisers to the US Centers for Disease Control and Prevention, ...

A federal vaccine advisory committee plans to review the childhood vaccination schedule and scrutinize vaccines that have ...

In the study, clesrovimab (MK-1654) significantly reduced the incidence of RSV disease and hospitalisations in healthy preterm and full-term infants, putting MSD in a position to potentially file ...

At the start of today’s meeting, ACIP's new chair, Martin Kulldorff, PhD, a statistician and epidemiologist formerly at ...

The FDA has started a review of MSD's respiratory syncytial virus (RSV) antibody clesrovimab, with a verdict due in the middle of next year. If approved by the 10th June action date, ...

A reshaped agenda for the Centers for Disease Control and Prevention’s vaccine advisory committee meeting on June 25–26 ...